NR1H4 and diabetic kidney disease: It has been reported that treatment with either FXR/TGR5 dual agonist INT-767 or TGR5 specific agonist INT-777 could prevent diabetic nephropathy through inducing Nrf2-mediated antioxidant generation, and reducing renal expression of oxidative stress [23,40].